Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Extracellular and intracellular small-molecule galectin-3 inhibitors.

Stegmayr J, Zetterberg F, Carlsson MC, Huang X, Sharma G, Kahl-Knutson B, Schambye H, Nilsson UJ, Oredsson S, Leffler H.

Sci Rep. 2019 Feb 18;9(1):2186. doi: 10.1038/s41598-019-38497-8.

2.

An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade.

Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SE, Gregory CD, Forbes SJ, Henderson NC, Zetterberg FR, Nilsson UJ, Leffler H, Ford P, Pederson A, Gravelle L, Tantawi S, Schambye H, Sethi T, Mackinnon AC.

Cancer Res. 2019 Jan 23. pii: canres.2244.2018. doi: 10.1158/0008-5472.CAN-18-2244. [Epub ahead of print]

PMID:
30674531
3.

A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.

Rajput VK, MacKinnon A, Mandal S, Collins P, Blanchard H, Leffler H, Sethi T, Schambye H, Mukhopadhyay B, Nilsson UJ.

J Med Chem. 2016 Sep 8;59(17):8141-7. doi: 10.1021/acs.jmedchem.6b00957. Epub 2016 Aug 23.

PMID:
27500311
4.

Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition.

Delaine T, Collins P, MacKinnon A, Sharma G, Stegmayr J, Rajput VK, Mandal S, Cumpstey I, Larumbe A, Salameh BA, Kahl-Knutsson B, van Hattum H, van Scherpenzeel M, Pieters RJ, Sethi T, Schambye H, Oredsson S, Leffler H, Blanchard H, Nilsson UJ.

Chembiochem. 2016 Sep 15;17(18):1759-70. doi: 10.1002/cbic.201600285. Epub 2016 Aug 12.

PMID:
27356186
5.

Assessing low-dose gentamicin-induced kidney injury in rats by analysis of urine.

Nykjaer A, Schambye H, Pedersen AH, Nielsen H.

J Pharmacol Toxicol Methods. 2009 Nov-Dec;60(3):316-20. doi: 10.1016/j.vascn.2009.07.006. Epub 2009 Jul 24.

PMID:
19632345
6.

Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study.

Hellström PM, Hein J, Bytzer P, Björnssön E, Kristensen J, Schambye H.

Aliment Pharmacol Ther. 2009 Jan;29(2):198-206. doi: 10.1111/j.1365-2036.2008.03870.x. Epub 2008 Oct 10.

7.

Transcriptome analysis of FSH and FSH variant stimulation in granulosa cells from IVM patients reveals novel regulated genes.

Perlman S, Bouquin T, van den Hazel B, Jensen TH, Schambye HT, Knudsen S, Okkels JS.

Mol Hum Reprod. 2006 Mar;12(3):135-44. Epub 2006 Mar 23.

PMID:
16556681
8.

Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone.

Perlman S, van den Hazel B, Christiansen J, Gram-Nielsen S, Jeppesen CB, Andersen KV, Halkier T, Okkels S, Schambye HT.

J Clin Endocrinol Metab. 2003 Jul;88(7):3227-35.

PMID:
12843169
9.

The effect of pH on beta(2) adrenoceptor function. Evidence for protonation-dependent activation.

Ghanouni P, Schambye H, Seifert R, Lee TW, Rasmussen SG, Gether U, Kobilka BK.

J Biol Chem. 2000 Feb 4;275(5):3121-7.

10.

Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations.

Perlman S, Costa-Neto CM, Miyakawa AA, Schambye HT, Hjorth SA, Paiva AC, Rivero RA, Greenlee WJ, Schwartz TW.

Mol Pharmacol. 1997 Feb;51(2):301-11.

PMID:
9203636
11.

Effect of different buffers on the biocompatibility of CAPD solutions.

Schambye HT.

Perit Dial Int. 1996;16 Suppl 1:S130-6. Review.

PMID:
8728179
12.

Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor.

Schambye HT, Hjorth SA, Weinstock J, Schwartz TW.

Mol Pharmacol. 1995 Mar;47(3):425-31.

PMID:
7700239
13.

Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor.

Perlman S, Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TW.

J Biol Chem. 1995 Jan 27;270(4):1493-6.

14.

Identification of peptide binding residues in the extracellular domains of the AT1 receptor.

Hjorth SA, Schambye HT, Greenlee WJ, Schwartz TW.

J Biol Chem. 1994 Dec 9;269(49):30953-9.

15.

Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists.

Schambye HT, von Wijk B, Hjorth SA, Wienen W, Entzeroth M, Bergsma DJ, Schwartz TW.

Br J Pharmacol. 1994 Oct;113(2):331-3.

16.

Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.

Schambye HT, Hjorth SA, Bergsma DJ, Sathe G, Schwartz TW.

Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7046-50.

17.

[Non-peptide antagonists to angiotensin II receptors. A review].

Schambye HT, Hjorth SA, Schwartz TW.

Ugeskr Laeger. 1993 Nov 1;155(44):3558-62. Review. Danish.

PMID:
8236577
18.

The cytotoxicity of continuous ambulatory peritoneal dialysis solutions with different bicarbonate/lactate ratios.

Schambye HT, Pedersen FB, Christensen HK, Berthelsen H, Wang P.

Perit Dial Int. 1993;13 Suppl 2:S116-8.

PMID:
8399544
19.

Bicarbonate- versus lactate-based CAPD fluids: a biocompatibility study in rabbits.

Schambye HT, Flesner P, Pedersen RB, Hardt-Madsen M, Chemnitz J, Christensen HK, Detmer A, Pedersen FB.

Perit Dial Int. 1992;12(3):281-6.

PMID:
1511044

Supplemental Content

Loading ...
Support Center